EIF4E and colorectal carcinoma: eFT508 treatment impaired the growth of three CRC organoids at 48 hr, and abrogated p-4E and reduced levels of p-4EBP1(S65/T70) and Myc at 24 hr, without affecting total eIF4E (Figure 2I–J).